

Gennadi Victor Glinsky, M.D., Ph.D.

Gennadi Victor Glinsky, M.D., Ph.D., is Head, Translational and Functional Genomics Laboratory, and Director, Translational & Functional Genomics Program at the Ordway Cancer Center, Ordway Research Institute, Inc, Albany, NY. He is an Adjunct Professor at the Department of Surgery, Division of Urology, Albany Medical College, in Albany, NY, Adjunct Professor at the Department of Pathology & Laboratory Medicine, Albany Medical College, in Albany, NY, and an Adjunct Associate Professor at the Sidney Kimmel Cancer Center in San Diego, CA. He is also a consultant for the National Institutes of Health and serves on the National Cancer Institute Review Panels. He serves as a reviewer on Review Panels for Israeli Science Foundation, Israel; Health Research Board (HRB), Ireland; Medical Research Council (MRC), United Kingdom; Swiss National Science Foundation, (SNF), Switzerland; Cancer Research UK, London, United Kingdom; Associazione Italiana per la Ricerca sul Cancro (AICR), Italy.

Dr. Glinsky holds membership to numerous professional organizations such as the American Association for the Advancement of Science, the American Association for Cancer Research and the Metastasis Research Society. Dr. Glinsky serves as a reviewer for various journals including the *Lancet*, *Journal of Clinical Investigation*, *Cancer Research*, *American Journal of Pathology*, *Proceedings of the National Academy of Science (PNAS)*, and *Oncogene*.

Dr. Glinsky is a major contributor to the invention, development, and practical implementation of the concept and principles of the “signature approach” to genome-wide microarray-based gene expression analysis. His recent work in the mouse/human cross-species translational genomics field has made a major impact on discovery of the genetic link between “stemness” phenotypes and therapy-resistance phenotypes of human cancer. He invented the gene expression-based cancer therapy outcome predictor (CTOP) algorithm and carry-out the retrospective clinical validation of the multi-signature CTOP algorithm for four distinct types of epithelial tumors, including breast, prostate, lung, and ovarian cancers. Dr. Glinsky’s lab was at the origin of discoveries of the links between metastatic behavior and apoptosis-resistance phenotypes and telomerase/telomere-dependent mechanisms of resistance to apoptosis. Dr. Glinsky is one of the originators of the concept of anti-adhesion cancer therapy and is a leading specialist in the field of anti-adhesion therapy of metastatic disease. He is a major contributor to the discovery and preclinical development of a novel family of low molecular weight therapeutic compounds named antimetastatic synthetic glycoamines.

Dr. Glinsky earned a doctor of medicine in internal medicine and general pathology. He later received his doctorate in experimental oncology and biochemistry from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev, Ukraine.